HUMACYTE INC
HUMANASDAQTrading Snapshot
- Day Range
- $0.70 – $0.72
- 52-Week Range
- $0.55 – $2.76
- Volume
- $3.61B
- Avg Volume
- $2.89B
- Shares Outstanding
- 269.6M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $495,000
- P/E Ratio
- —
- P/S Ratio
- 117.1x
- EPS (TTM)
- $-0.57
- Dividend Yield
- —
Why Investors Own HUMA
- ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HUMACYTE INC
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.